Fact-checked by Grok 2 weeks ago

Eric Topol


Eric Topol is an American cardiologist, scientist, and author specializing in the application of genomics, digital tools, and artificial intelligence to advance individualized medicine.
He earned a B.A. in biomedicine from the University of Virginia in 1975 and an M.D. from the University of Rochester in 1979, followed by residency and fellowship training at the University of California, San Francisco, and Johns Hopkins University. After serving as a tenured professor at the University of Michigan, Topol became Chief of Cardiovascular Medicine at the Cleveland Clinic, where he elevated its cardiology program to national prominence and founded the Lerner College of Medicine. In 2007, he joined Scripps Research as Executive Vice President, Professor of Translational Medicine, and founder-director of the Scripps Research Translational Institute, focusing on translating genomic and digital innovations into clinical practice. Topol has authored over 1,300 peer-reviewed articles, accumulating more than 300,000 citations, and ranks among the world's top 10 most cited researchers in medicine; he is also a member of the . His books, including The Creative Destruction of Medicine, The Patient Will See You Now, Deep Medicine, and Super Agers, advocate for patient-empowered, technology-driven healthcare. As principal investigator for major NIH initiatives like the Research Program and Clinical Translational Science Award, he has driven large-scale efforts in precision medicine. Topol's career includes notable critiques of pharmaceutical practices, such as his analysis of Merck's handling of Vioxx cardiovascular risks, which highlighted conflicts between commercial interests and evidence. During the , he emphasized rigorous data over expedited approvals, questioning the efficacy claims for treatments like convalescent plasma and based on trial shortcomings. These positions underscore his commitment to empirical validation amid institutional pressures.

Early Life and Education

Upbringing and Family Influences

Eric Topol was born on June 26, 1954, in Queens, New York, and raised in the Long Island suburb of Oceanside. His parents were not involved in medicine; his mother worked as a schoolteacher, and his father was an accountant. As a child, Topol witnessed his father's severe diabetes, fostering an early curiosity about why health conditions appeared to cluster within families and prompting questions about underlying genetic and environmental factors. This observation, rather than direct familial involvement in healthcare, represented a key personal influence on his eventual focus on cardiovascular genetics and preventive medicine. Topol demonstrated academic precocity, skipping two grades in high school due to boredom with the curriculum, which allowed him to enter college at age 15. Despite this aptitude, he lacked initial ambitions in , with no reported professional or vocational guidance from his family steering him toward science or healthcare during his formative years.

Academic Training and Early Medical Career

Topol earned a Bachelor of Arts degree in biomedicine from the University of Virginia in 1975. He subsequently obtained his Doctor of Medicine degree from the University of Rochester School of Medicine and Dentistry in 1979. After completing medical school, Topol undertook his residency in internal medicine at the University of California, San Francisco, from 1979 to 1982, where he worked under the mentorship of cardiologist Kanu Chatterjee. He then pursued a cardiology fellowship at Johns Hopkins University from 1982 to 1985. Topol launched his early academic medical career as a tenured professor in the Department of at the , holding the position from 1985 to 1991 and concentrating on cardiovascular research and clinical practice. During this period, he contributed to advancements in and , establishing a foundation for his later leadership roles.

Professional Career

Initial Academic and Clinical Roles

Following completion of his internal medicine residency at the (1979–1982) and cardiology fellowship at (1982–1985), Topol assumed his initial academic position as a of internal medicine with tenure in the Department of Internal Medicine at the Medical School in 1985. In this role, he directed the cardiac catheterization laboratories and the interventional cardiology unit, managing diagnostic and therapeutic procedures including balloon angioplasty for . Topol's early clinical practice at emphasized , where he performed catheter-based interventions for patients with acute coronary syndromes and contributed to the integration of thrombolytic agents like recombinant tissue plasminogen activator (tPA) with techniques, building on trials he co-led during his fellowship. He balanced these duties with teaching medical students and residents in cardiovascular medicine, fostering a focus on evidence-based procedural advancements. During his six-year tenure at Michigan (1985–1991), Topol published foundational work on angioplasty outcomes and antiplatelet therapies, establishing his expertise in translating laboratory innovations to bedside applications while maintaining patient care volumes typical of a high-volume academic center. These roles solidified his reputation in cardiovascular genetics and device development prior to his transition to larger institutional leadership.62216-7/fulltext)

Leadership at Major Institutions

Topol served as chairman of the Department of Cardiovascular Medicine at the from 1991 until 2005, during which he founded the Lerner College of Medicine of in 2002 and led the institution's program to become the top-ranked in the United States by 2004.62216-7/fulltext) His tenure involved directing large-scale clinical trials in and expanding the clinic's research infrastructure, though it ended amid a dispute with clinic leadership over his public criticism of Vioxx in 2004.62216-7/fulltext) In 2006, Topol established the Scripps Research Translational (now Scripps Research Translational Institute) with a $54 million endowment from the and assumed the role of its founding director. He joined as chief academic officer in 2007, overseeing integration of research and clinical care across its network of hospitals and clinics. At Scripps Research, he was appointed executive vice president in December 2017, a position focused on advancing translational medicine, while also serving as chair of the Department of Translational Medicine and professor of molecular medicine. Under his leadership, the institute pioneered initiatives in , , and precision medicine, including the first wireless FDA-approved cardiac monitor in 2009.

Founding and Directing Translational Initiatives

In 2007, Eric Topol founded the (SRTI), formerly known as the Scripps Translational Science Institute, as a collaborative effort between and to expedite the application of biomedical discoveries to patient care, with a core focus on individualized medicine. The institute's establishment addressed gaps in traditional research pipelines by prioritizing rapid translation from laboratory findings to clinical interventions, leveraging Topol's expertise in and cardiovascular medicine. Under his direction, SRTI has integrated multidisciplinary approaches, including wireless health monitoring and genomic sequencing, to develop predictive models for disease prevention and treatment personalization. As founder and ongoing director, Topol serves as chair of Translational Medicine and professor at Scripps Research, where he has secured major funding to sustain these efforts, such as a $20 million NIH Clinical and Translational Science Award in 2008 for advancing consortium-based research networks. He also leads as principal investigator for significant NIH programs, including components of the All of Us Research Program, which enrolls over one million participants to generate diverse datasets for precision medicine applications. These initiatives emphasize empirical validation through large-scale clinical trials and data integration, aiming to reduce the typical 17-year lag between discovery and implementation observed in medical research. Topol's leadership at SRTI extends to fostering education and training in translational science, including programs for clinician-scientists and community engagement to incorporate into research protocols. His role has positioned the institute as a hub for in biomarkers and AI-driven diagnostics, with outputs including FDA-approved technologies derived from institute-led projects.

Scientific Research and Contributions

Advances in Genomics and Cardiovascular Genetics

Topol advanced cardiovascular genetics through early identification of rare mutations underlying familial myocardial infarction. In 2003, his team described a seven-amino-acid in-frame deletion in the MEF2A transcription factor gene segregating with autosomal dominant coronary artery disease and myocardial infarction in a multigenerational pedigree, representing an initial example of a monogenic contributor to a typically polygenic condition. This finding implicated disrupted endothelial integrity and vascular inflammation in disease pathogenesis, as MEF2A regulates genes involved in artery wall protection against atherosclerosis. Building on this, Topol's work extended to common variants modulating heart attack risk via inflammatory pathways. He contributed to studies validating haplotypes in ALOX5AP (encoding 5-lipoxygenase-activating protein) and related genes (LTA4H, LTC4S) as susceptibility factors for , with odds ratios of 1.5–2.0 in replication cohorts across European and Asian populations. These variants enhance production, promoting plaque instability and , and informed pharmacogenomic trials targeting the pathway with inhibitors like zileuton or antagonists. Similarly, his group identified a THBS4 variant associated with , further linking dysregulation to acute events. Topol synthesized these insights in comprehensive reviews of heart attack , tracing evolution from candidate approaches to genome-wide studies (GWAS) that uncovered loci like 9p21 (explaining ~10% of population-attributable risk via ANRIL regulation of vascular smooth muscle proliferation). He emphasized translational potential, including polygenic risk scores (PRS) aggregating thousands of variants to stratify susceptibility, with high PRS conferring 2–3-fold lifetime risk elevation independent of traditional factors like LDL cholesterol. At , Topol launched the in 2007, a integrating whole-genome sequencing or with deep phenotyping from electronic health records in thousands of participants to model cardiovascular trajectories and test PRS clinical utility. This facilitated validation of GWAS hits in real-world settings and pharmacogenomic applications, such as SLCO1B1 variants predicting risk in heart disease patients. His efforts underscored ' role in shifting from reactive to preventive , though he noted limitations like modest effect sizes and ethnic biases in variant discovery requiring diverse cohorts for .

Integration of AI in Diagnostics and Treatment

Topol has extensively promoted the use of (AI) to enhance diagnostic accuracy in medicine, particularly through automated analysis of and multimodal data integration. In his 2019 book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again, he argues that AI excels at tasks inherent to diagnostics, such as interpreting electrocardiograms, scans, and slides, thereby reducing human error rates that contribute to approximately 10-15% of diagnoses. He posits that algorithms, trained on large datasets, can achieve or surpass radiologist-level performance in detecting conditions like from chest X-rays or from retinal images, as demonstrated in benchmark studies where AI sensitivity reached 94% compared to 91% for clinicians. Building on this, Topol's research emphasizes AI systems that synthesize text, images, and genomic data for more robust diagnostics. A 2023 perspective in Science co-authored by Topol highlights how foundation models processing diverse inputs—such as electronic health records alongside —enable earlier detection of diseases like cancer or cardiovascular events by identifying subtle correlations missed by single-modality approaches. Similarly, in a 2025 Cell article, he describes generative AI's role in simulating patient trajectories from inputs, improving diagnostic precision through probabilistic reasoning akin to clinical synthesis, with applications in forecasting onset or tumor progression where model accuracy exceeded 85% in validation cohorts. These advancements, Topol contends, stem from AI's capacity to process vast datasets without fatigue, though he cautions that real-world efficacy depends on high-quality, unbiased training data to mitigate algorithmic errors observed in underrepresented populations. In treatment planning, Topol advocates AI-driven personalization, leveraging to optimize therapies based on individual patient profiles. His work underscores AI's potential in cardiovascular medicine, where models forecast drug responses or procedural outcomes, as in simulations reducing adverse events by 20-30% through counterfactual reasoning—evaluating "what-if" scenarios for interventions like placement. For instance, generative models detailed in recent publications integrate clinical notes, labs, and imaging to recommend tailored regimens, outperforming traditional guidelines in retrospective analyses of conditions like , where AI-augmented decisions aligned with 92% of optimal paths versus 78% for unaided physicians. Topol stresses that such tools should augment rather than replace clinicians, citing evidence from controlled studies where hybrid human-AI systems yielded superior results to either alone, though deployment challenges like regulatory validation and data privacy remain unresolved.

Development of Digital Health Technologies

Topol founded and directed the Translational Institute in 2006, where he integrated technologies such as wireless sensors and mobile devices to enable real-time patient monitoring and . Under his leadership, researchers pioneered the use of biosensors to detect early physiological changes, including airway constriction in patients prior to symptom onset, facilitating proactive interventions. This work emphasized frequent, patient-generated data collection via mobile platforms, such as hundreds of weekly readings, to improve disease management over traditional sporadic clinical assessments. From approximately 2007, coinciding with proliferation, Topol advanced digital medicine by developing applications for wearable sensors and point-of-care diagnostics, including smartphone-linked imaging and lab assays for real-world health data generation. He personally adopted handheld devices in starting in 2009, replacing stethoscopes for cardiac assessments and demonstrating the feasibility of portable, high-fidelity diagnostics. In 2018, Topol co-launched the journal npj Digital Medicine with Nature Research through the Scripps Translational Science Institute, establishing standards for validating digital tools like telemedicine and sensor-based monitoring via randomized controlled trials. Topol's initiatives extended to digital clinical trials at the Digital Trials Center, including the 2023 PROGRESS study, which utilized participant-tracked digital metrics for remote biomedical research evaluation. In December 2021, under his oversight at the Translational Institute, scientists developed an AI-based system leveraging wearable devices to detect infections through in physiological signals, such as , prior to confirmatory testing. These efforts underscored Topol's focus on causal mechanisms in digital data, prioritizing empirical validation to mitigate overreliance on unproven consumer-grade sensors amid varying regulatory scrutiny.

Explorations in Aging and Longevity Science

Topol's explorations in aging and longevity emphasize extending healthspan—the period of life free from major chronic diseases—through evidence-based prevention rather than speculative interventions like anti-aging supplements or reversal of chronological aging. In his 2025 book Super Agers: An Evidence-Based Approach to Longevity, he synthesizes recent advances in biomarkers and immunology to argue that individuals over age 85 without cancer, cardiovascular disease, or neurodegenerative conditions represent achievable "super agers" via targeted strategies grounded in primary prevention. The work highlights 12 hallmarks of aging, including genome instability, telomere attrition, and mitochondrial dysfunction, as interconnected drivers amenable to modulation, while critiquing hype around unproven therapies in favor of validated tools like vaccines and lifestyle modifications. A core focus is biological age assessment via "clocks" that outperform chronological metrics in predicting health outcomes. Topol discusses epigenetic clocks, such as the DNAm IC model developed at the Buck Institute, which integrates DNA methylation patterns from saliva to link biological age with immune function, inflammation, and modifiable factors like physical activity and omega-3 intake; this clock demonstrates superior accuracy over earlier models like Horvath's in forecasting healthspan. Complementing these are proteomic organ clocks, derived from blood-based analysis of thousands of proteins, which enable organ-specific aging tracking for the brain, heart, liver, kidneys, and immune system, facilitating early detection of accelerated decline. He integrates AI to refine these tools, such as using retinal imaging to predict Alzheimer's risk 5–7 years in advance or blood tests for amyloid plaque buildup, underscoring their role in proactive monitoring. Topol identifies immunosenescence and chronic low-grade inflammation ("inflammaging") as pivotal drivers of age-related diseases, proposing an "I/I" model where immune decline fuels (SASP) proteins that predict frailty and elevate markers like and IL-6. Prevention potential is quantified: up to 80% of cardiovascular cases, 40% of cancers, and 45% of Alzheimer's are avertable through interventions prioritizing immune resilience over genetic determinism, with the immune system's TCF7 pathway highlighted for countering inflammation and promoting longevity. Evidence-based tactics include vaccines (e.g., vaccination reducing dementia risk), GLP-1 receptor agonists for metabolic control, and lifestyle pillars—reducing ultra-processed foods, enhancing and exercise, and adopting diets—to mitigate these drivers, supported by longitudinal data showing immune strength as a stronger correlate of healthy aging than . For high-risk groups, he advocates active with periodic imaging and panels to preempt disease onset.

Policy and Institutional Initiatives

Oversight of Precision Medicine Programs

Eric Topol served as a for the Research Program, a key component of the U.S. National Institutes of Health's (NIH) Precision Medicine Initiative launched in 2015, which evolved from the Precision Medicine Initiative Cohort Program. In 2016, Topol received a $207 million NIH grant to lead efforts at the Translational Institute, focusing on recruiting and engaging at least 100,000 participants from diverse, under-represented populations to build a national research cohort of over one million individuals for advancing precision medicine through genomic, environmental, and behavioral . This role involved overseeing participant enrollment strategies, protocols, and the development of tools for consumer-facing engagement, such as mobile health applications to facilitate broad . Under Topol's direction, the initial phase secured $20 million in funding for the first year, emphasizing genomic sequencing and longitudinal aggregation to enable into prevention and personalized treatments. His oversight extended to ensuring ethical and privacy protections, aligning with the program's goals of democratizing access to precision medicine insights while addressing gaps in representation among existing biobanks, which historically underrepresented minorities and rural populations. By , the program had enrolled over 300,000 participants, with Topol's leadership credited for advancing AI-driven analytics to derive actionable insights from the cohort's multimodal datasets. Topol's contributions included advocating for the initiative's shift toward prospective, generation over retrospective studies, positioning it as a foundational platform for in precision medicine. However, challenges under his purview included scaling recruitment amid privacy concerns and ensuring data across healthcare systems, with ongoing evaluations highlighting the need for robust to mitigate biases in algorithmic applications derived from the .

NHS Topol Review and Digital Fellowships

In April 2018, the UK Department of Health and Social Care commissioned Eric Topol to lead an independent review into how emerging technologies, including , , and , could transform the (NHS) workforce. Published on 11 February 2019 as Preparing the healthcare workforce to deliver the digital future, the Topol Review emphasized integrating digital tools to enhance patient care while addressing workforce skill gaps. It highlighted four key technology domains— and augmented intelligence, , , and immersive technologies—and recommended embedding education in these areas across NHS training programs to foster a "digitally savvy" workforce capable of leveraging data-driven diagnostics and . The review proposed creating specialized roles, such as clinical informaticians, and allocating dedicated time for staff to develop digital competencies, aligning with the NHS Long Term Plan's goal of improving efficiency amid rising demands. The Topol Review's recommendations directly influenced the establishment of the Topol Programme for Digital Fellowships in Healthcare, launched by in 2019 to build capacity in . This initiative allocated £500,000 to fund 20 fellowships initially, enabling clinical staff to dedicate 20% of their time over 12 months to acquiring skills in areas like data analytics, , and through a mix of academic modules, project work, and mentorship. Subsequent cohorts expanded the program, with fellows undertaking real-world projects such as implementing for or genomic data integration, aimed at scaling innovations across NHS trusts. By 2023, evaluations noted progress in embedding , though challenges persisted in resource allocation and cultural adoption within the NHS. Topol's involvement extended to advisory roles, underscoring the program's focus on practical, evidence-based digital upskilling to support causal improvements in clinical outcomes.

Contributions to Public Health Frameworks

Topol authored a 2019 independent review commissioned by Health Education , titled Preparing the Healthcare Workforce to Deliver the Digital Future, which outlined a framework for integrating , , and digital technologies into the UK's (NHS) workforce training and practice to enhance patient care efficiency and outcomes. The review recommended embedding across all healthcare roles, fostering interdisciplinary education, and leveraging data-driven tools to address workforce shortages and improve diagnostic accuracy, projecting that could automate up to 20% of clinical tasks by 2030. It emphasized ethical implementation, data privacy, and equitable access, influencing NHS policy on digital fellowships and upskilling programs launched subsequently. In the context of pandemic response, Topol co-authored a 2020 JAMA Viewpoint proposing a structured framework for deploying digital technologies in COVID-19 management, including widespread use of wearable devices for real-time symptom tracking, AI-enabled contact tracing, and telemedicine to reduce transmission and hospital burdens. This approach advocated for federated data platforms to aggregate anonymized health signals from millions of users, enabling predictive modeling of outbreaks with granularity down to local levels, as demonstrated by early integrations with Apple Health and data during the pandemic's initial waves. The framework highlighted causal linkages between digital surveillance and reduced case fatality rates, drawing on empirical data from regions with high adoption, such as South Korea's app-based systems, while cautioning against over-reliance without robust safeguards. Topol's leadership in the National Institutes of Health's Research Program, funded by a $207 million grant awarded in 2016, established a framework for precision through a prospective of over one million diverse participants, generating genomic and phenotypic data to inform population-level interventions. This initiative prioritizes underrepresented groups to mitigate biases in traditional datasets, enabling causal analyses of genetic-environmental interactions for disease prevention, with applications in tailoring strategies for conditions like and . By 2025, the program's data repository supported over 500 research projects, underscoring its role in shifting from reactive to predictive paradigms grounded in large-scale .

Controversies and Public Disputes

Involvement in Vioxx Safety Concerns and Financial Ties

Eric Topol, as chairman of cardiovascular medicine at the , was among the earliest prominent researchers to publicly highlight potential cardiovascular risks associated with (Vioxx), a selective COX-2 inhibitor approved by the FDA on May 20, 1999, for arthritis treatment. In a published on August 22, 2001, in the Journal of the American Medical Association, Topol and colleagues and Steven Nissen analyzed data from the VIGOR trial (8,076 patients) and other studies, finding that selective COX-2 inhibitors like rofecoxib were associated with an approximate twofold increase in the risk of compared to nonselective NSAIDs or placebo, particularly in the absence of aspirin cardioprotection. They recommended that pharmaceutical sponsors conduct dedicated cardiovascular endpoint trials to assess long-term safety, a call that Merck did not heed despite the signals. Topol continued to amplify these concerns through subsequent publications and public statements. In September 2004, shortly before Merck's voluntary withdrawal of rofecoxib on September 30, 2004—following the APPROVe trial's demonstration of doubled cardiovascular event risk after 18 months of use—he authored an editorial in the Cleveland Clinic Journal of Medicine titled "The sad story of Vioxx, and what we should learn from it," estimating that tens of thousands of patients may have experienced major adverse events attributable to the drug and critiquing inadequate post-approval safety monitoring. That October 21, 2004, he published "Failing the Public Health — Rofecoxib, Merck, and the FDA" in the New England Journal of Medicine, arguing that Merck prioritized $2.5 billion in annual sales and over $100 million in over conducting necessary cardiovascular safety studies, while faulting the FDA for passivity, including a two-year delay in convening an advisory committee after initial risk signals in 2001. Topol asserted that rofecoxib's risks were evident as early as and could precipitate heart attacks at any point after initiation, a position vindicated by the drug's market removal after use by over 80 million patients. These efforts drew scrutiny over Topol's financial ties to Great Point Partners, a whose Biomedical Value Fund had shorted Merck stock prior to the Vioxx withdrawal, profiting from the subsequent decline in Merck's share price. Topol served as a paid advisor to the fund, receiving $12,000 annually, and the fund cited his warnings about Vioxx's cardiac risks in investor communications, such as a statement that "Eric Topol M.D., Chairman of Cardiovascular at the , has been warning investors about Vioxx for some time." In disclosures accompanying his 2004 NEJM editorial, Topol acknowledged the advisory role and the fund's trading in Merck stock. Critics, including Merck defenders, questioned whether this arrangement influenced his advocacy, suggesting potential conflicts despite the peer-reviewed nature of his earlier 2001 predating documented fund positions. Topol denied any awareness of the fund's specific Merck investments, stated he never discussed Vioxx or Merck with fund principals, and affirmed he held no financial stake in the fund's performance. To mitigate perceptions of conflict, he resigned from the advisory role in late 2004 and, by January 2005, severed broader ties, emphasizing that his critiques stemmed from clinical data rather than financial incentives. Subsequent analyses, including a 2005 of 23,407 patients confirming rofecoxib's 0.74% rate versus 0.52% for , supported the validity of Topol's risk assessments independent of the hedge fund association.

Conflict and Departure from Cleveland Clinic

In December 2005, Eric Topol was relieved of his positions as provost of the Lerner College of Medicine and chief academic officer, roles he had held since helping establish the institution in 2002, with the clinic citing an administrative reorganization approved by its board of trustees on December 12. Topol, who had served as chairman of the clinic's department of cardiovascular medicine since 1991, suggested the move was linked to his recent deposition in a federal Vioxx lawsuit, where he accused Merck of "scientific misconduct" in downplaying the drug's cardiovascular risks—a criticism he had amplified since co-authoring a 2001 study highlighting those dangers. Instead of his usual one-year contract renewal, Topol received a six-month agreement, amid reports of tensions following alleged pressure from Merck's CEO on clinic leadership over his Vioxx advocacy, though Merck denied such contact. The ouster exacerbated a yearlong dispute between Topol and clinic CEO Delos "Toby" Cosgrove, centered on institutional conflicts of interest in research and financial ties to industry. An internal review by the law firm McDermott, Will & Emery, prompted by broader scrutiny of researcher-industry relationships, found "inattention" to conflict disclosures at the clinic, leading to tightened ethics policies on financial interests and advertising by drug companies. Topol's external roles, including advising an investment fund that shorted Merck stock after his Vioxx warnings, drew additional controversy, as reported by Fortune magazine, though he maintained these aligned with his evidence-based critiques of unsafe drugs. On February 9, 2006, Topol announced his resignation from the clinic to join as a professor of and cardiovascular , retaining his chairmanship only until the transition. He described the departure as an opportunity to focus on research passions free from administrative burdens, while negotiating his exit with a involved in Merck litigation. The clinic's overhaul of disclosure rules followed shortly, reflecting systemic issues Topol had pushed to address, though his exit marked the end of his 15-year tenure that had elevated its profile.

Critiques of COVID-19 Response Measures

Eric Topol has been a prominent critic of various aspects of the response, particularly emphasizing shortcomings in data transparency, regulatory decisions, and communication. In 2020, he led a campaign via and an signed by over 60 scientists urging caution against authorizing a before the U.S. , arguing that political pressures could compromise scientific rigor and public trust. He contended that expedited approvals risked overlooking long-term safety data, especially given the vaccines' novel mRNA technology, and advocated for Phase 3 trials to fully assess efficacy against severe disease rather than just infection prevention. Topol sharply criticized the U.S. Food and Drug Administration's (FDA) (EUA) for convalescent in August 2020, describing it as based on flawed observational data showing minimal benefit and potentially diverting resources from proven therapies. In a open letter to FDA Commissioner , he highlighted how the announcement exaggerated claims from a study with a of just 1.3% for mortality, lacking evidence, and warned it could undermine confidence in regulatory processes. Similarly, in March 2021, he labeled AstraZeneca's initial U.S. data reporting as "disturbing" for omitting updated figures from a full , which later showed 76% effectiveness against symptomatic , arguing such lapses fueled unnecessary skepticism. Throughout the pandemic, Topol faulted federal agencies for inadequate surveillance and communication, attributing the Biden administration's response failures—such as during the surge—to deficient wastewater and genomic sequencing , which hampered variant tracking and policy adjustments. He described the Centers for Disease Control and Prevention's (CDC) handling of public messaging as a "historic botched job," citing inconsistent guidance on masks, boosters, and risks that eroded credibility. In March 2024, Topol expressed ongoing disappointment with the CDC's updated isolation guidelines, which dropped requirements for negative tests before ending , asserting this ignored persistent and risks supported by studies showing up to 10 days post-symptoms. Topol also critiqued broader policy overreach, including school closures and lockdowns, advocating for targeted protections based on risk stratification rather than blanket measures, while supporting but opposing universal mandates for low-risk groups like children without robust long-term data. His positions, disseminated through his newsletter Ground Truths and media appearances, positioned him as a skeptic of institutional narratives, though he consistently endorsed vaccines' role in reducing severe outcomes when transparently evaluated.

Publications and Public Intellectual Role

Major Books and Authored Works

Eric Topol has authored four bestselling books focusing on the transformation of through , , , and longevity science. These works emphasize patient empowerment, data-driven , and the of tools to improve healthcare outcomes. His first major book, The Creative Destruction of Medicine: How the Digital Revolution Will Create Better , published in 2012 by , argues that advancements in , wireless sensors, and mobile devices will disrupt traditional medical practices, enabling individualized care over standardized protocols. Topol draws on examples from and to illustrate how and tools can shift medicine from reactive to predictive models. Published in 2015, The Patient Will See You Now: The Future of Medicine is in Your Hands () extends these ideas by advocating for patient-centered healthcare, where smartphones and apps allow individuals to access their own genomic data, monitor , and bypass intermediaries for direct consultations. Topol posits that this will invert the conventional doctor-patient dynamic, fostering greater while challenging regulatory and hurdles. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again (Basic Books, 2019) examines artificial intelligence's potential to alleviate clinician burnout and enhance diagnostics, such as through image analysis in radiology and predictive algorithms for disease progression. Topol cautions against over-reliance on AI without human oversight, highlighting applications in precision medicine while addressing ethical concerns like data bias and algorithmic transparency. Topol's most recent book, Super Agers: An Evidence-Based Approach to Longevity (, May 6, 2025), synthesizes research on exceptional aging, integrating insights from , interventions, and emerging therapies like senolytics to promote extended healthspan. It critiques chronological age as a poor predictor of biological vitality, advocating for multimodal strategies grounded in clinical trials and longitudinal studies.

Media Commentary and Advocacy Efforts

Topol has maintained an active presence in medical media as Editor-in-Chief of since 2017, where he authors editorials and hosts the "One-on-One with Eric Topol" , interviewing experts on topics ranging from clinical innovations to challenges. Through these platforms, he emphasizes data-driven critiques of healthcare inefficiencies, such as clinician exacerbated by administrative burdens, advocating for systemic reforms to prioritize patient-centered care. In November 2023, Topol launched the "Ground Truths" Substack newsletter, which by 2025 had amassed subscribers for its weekly dissections of peer-reviewed studies on public health issues, including suboptimal diets contributing to chronic diseases and chronic lead exposure as an underrecognized cardiovascular risk factor. In these posts, he promotes rigorous, evidence-based interventions over anecdotal wellness fads, such as highlighting the need for large-scale trials on nutrition's causal role in longevity rather than relying on observational correlations. He has also used the newsletter to question the persistence of preventable conditions like heart disease amid declining infectious disease mortality, urging policy focus on lifestyle-modifiable risks. Topol's advocacy extends to championing artificial intelligence and digital tools to overhaul medicine, frequently appearing in interviews and writings to argue that AI can outperform humans in pattern recognition for diagnostics while freeing physicians for empathetic interactions. In a January 2025 JAMA essay co-authored with colleagues, he proposed creating Master of Digital Health degree programs to equip future leaders with skills in AI integration, genomics, and wearable data analytics, citing the rapid evolution of these technologies as necessitating formal training beyond ad-hoc adoption. His 2025 book Super Agers further amplifies this through media circuits, including PBS discussions, where he delineates evidence hierarchies for extending healthspan via polygenic risk scoring, proteomics, and targeted interventions like exercise and senolytics, while cautioning against overhyped anti-aging therapies lacking randomized trial validation. These efforts position him as a proponent of "deep medicine," where computational tools enable precision over one-size-fits-all approaches, though he acknowledges economic barriers to equitable implementation.

Honors and Recognitions

Academic and Professional Awards

Eric Topol was elected to the (formerly the Institute of Medicine) in 2004 in recognition of his distinguished contributions to medical science. He is also a member of the Association of American Physicians, the American Society of Clinical Investigation, and the Society of Scholars. In cardiovascular medicine, Topol received the Simon Dack Award from the for outstanding contributions to clinical . He was awarded the 2011 TCT Career Achievement Award by the Cardiovascular Research Foundation for pioneering advancements in interventional cardiovascular medicine. The Libin/AHFMR Prize in Cardiovascular Research followed in 2012 for his significant research impacts in the field. Topol earned the Wallace H. Coulter Lectureship Award from the American Association for Clinical Chemistry in 2014, honoring his integration of laboratory science with clinical practice. In 2016, he received the Rambam Award from for his innovations in and technology. For broader contributions to and communication in healthcare, Topol was presented with the Arnold P. Gold Foundation's National Humanism in Medicine Medal in 2021. In 2024, he received the Donald A.B. Lindberg Distinguished Health Communications Award from the Friends of the of Medicine for advancing health information dissemination. His alma mater, the , conferred the Hutchinson Medal, its highest honor, acknowledging his lifetime achievements in .

Citations and Institutional Honors

Topol's scholarly output has garnered extensive citations, reflecting his influence in fields such as cardiovascular , , and . As of October 2025, his profile records over 378,000 total citations across more than 1,300 peer-reviewed publications. His stands at 238, indicating 238 papers each cited at least 238 times, a metric underscoring sustained impact. These figures position him among the most cited researchers globally in , with rankings placing him in the top echelons for discipline-specific in medical sciences. Institutionally, Topol was elected to the (formerly the Institute of Medicine) in 2004, recognizing his contributions to advancing medical science and policy. He is also a member of the American Society for Clinical Investigation, an elite for physician-scientists demonstrating exceptional research achievement. Additional institutional recognitions include the Hutchinson Medal, the University of Rochester's highest alumni honor, awarded for his foundational work in and . In 2021, he received the Arnold P. Gold Foundation Humanism in Medicine Medal for exemplary leadership in patient-centered care and innovation. More recently, Topol was honored with the Friends of the National Library of Medicine's Donald A.B. Lindberg Distinguished Health Communications Award in 2024, acknowledging his role in disseminating evidence-based health information through public platforms and authorship. These honors complement his leadership in major NIH-funded initiatives, such as serving as principal investigator for the All of Us Research Program, though such roles emphasize programmatic impact over formal accolades.

Personal Life

Family Background and Private Interests

Eric Topol was born on June 26, 1954, and raised in by non-medical parents; his mother worked as a schoolteacher, while his father was an . A history of health challenges within his family, including relatives lost to cancer during his youth and his mother's death from cancer as a smoker, profoundly influenced his interest in from an early age. 30026-5.pdf) Topol has been married to Susan Merriman Topol for over 45 years as of 2025, having wed around 1979. The couple has two children and three grandchildren, whom Topol has described as sources of personal fulfillment amid his professional commitments. Details on Topol's private interests beyond family remain limited in public records, though he maintains personal health practices such as , prioritizing , and adhering to a , which he credits for his biological heart age being 13 years younger than his chronological age at 71. These habits align with his research focus on but reflect individual routines rather than broader hobbies like or puzzles, which he has noted in patients but not personally claimed.

References

  1. [1]
    Eric Topol, MD - Scripps Research
    Education. M.D. (Medicine), University of Rochester, School of Medicine and Dentistry, 1979 B.A. (Biomedicine), University of Virginia, 1975. Professional ...
  2. [2]
    Eric Topol Biography - Scripps Research
    Eric Topol, chair and professor of Translational Medicine, is an executive vice president at Scripps Research and the founder and director of the Scripps ...
  3. [3]
    Failing the Public Health — Rofecoxib, Merck, and the FDA
    Sadly, it is clear to me that Merck's commercial interest in rofecoxib sales exceeded its concern about the drug's potential cardiovascular toxicity. Had the ...Missing: controversy | Show results with:controversy
  4. [4]
    Researcher Criticizes FDA's Exaggeration Of Plasma's Efficacy In ...
    Aug 25, 2020 · Eric Topol of the Scripps Research Translational Institute about his concerns about the use of convalescent plasma for COVID-19 treatment.
  5. [5]
    The 'very, very bad look' of remdesivir, the first FDA-approved ...
    Oct 28, 2020 · "This is a very, very bad look for the FDA, and the dealings between Gilead and EU make it another layer of badness," says Eric Topol, a ...
  6. [6]
    https://erictopol.substack.com/
  7. [7]
    [PDF] Lost in Translation - Geoffrey Beene Foundation
    Born in Queens, New York and raised in the Long Island suburb of Ocean- side, Topol was bored with high school, having skipped two grades. At just 15, he ...
  8. [8]
    Eric Topol, MD - Sanford Health News
    May 26, 2022 · You know, you, you mentioned family as a first description of you, and I know you're a family man. Who was Eric Topol as a child, you know, as ...Missing: background upbringing
  9. [9]
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30026-5/fulltext
  10. [10]
    Exciting Interventions in Individualized Medicine - NIH
    Topol did his residency at the University of California, San Francisco, where cardiologist Kanu Chatterjee, MBBS, was a vital mentor. “He really gave me the ...
  11. [11]
    Eric Topol - The Lancet
    He taught at the University of Michigan before taking up his current position in 1991 as chairman of cardiology at the Cleveland Clinic Foundation. Who was your ...Missing: career timeline
  12. [12]
    Univ of Michigan Creates Eric J. Topol Professorship - Scripps Health
    Oct 25, 2011 · Eric Topol, MD, cardiologist and chief academic officer at Scripps Health. The University of Michigan Medical School today announced ...
  13. [13]
    Interview With Eric J. Topol, MD - American College of Cardiology
    Jan 20, 2021 · Prior to coming to Scripps in 2007, he led the Cleveland Clinic to become the number one center for heart care and founded the physician- ...Missing: timeline | Show results with:timeline
  14. [14]
    Eric J. Topol, MD | myadlm.org
    A practicing cardiologist, he has led the flagship, National Institutes of Health-supported Scripps Translational Science Institute since 2006, where he works ...
  15. [15]
    Top heart doctor leaving Cleveland Clinic - NBC News
    Feb 10, 2006 · Topol attacked Vioxx while working as a consultant for a hedge fund that was betting against the drug's manufacturer. He also has criticized the ...
  16. [16]
    Scripps Eric Topol Among 10 Most Influential
    Apr 22, 2013 · Scripps Health Chief Academic Officer Eric Topol, MD, has been named one of the 10 most influential physician executives by Modern Healthcare magazine.
  17. [17]
    Eric Topol named executive vice president at The Scripps Research ...
    Dec 20, 2017 · Eric Topol, MD, the founder and director of STSI, has been named executive vice president at TSRI. Peter Schultz, PhD, will continue in his role as TSRI ...
  18. [18]
    Scripps Research Translational Institute
    The Scripps Research Translational Institute, formerly named Scripps Translational Science Institute (STSI), was founded in 2007 with one essential aim.About · Translational Research · Education and Training · Community Engagement
  19. [19]
    Scripps Translational Science Gets $20M NIH Grant
    May 28, 2008 · The consortium created by CTSA members was formed in 2006 and currently includes 38 organizations across the nation, including STSI. When the ...
  20. [20]
    Mutation of MEF2A in an inherited disorder with features of coronary ...
    Nov 28, 2003 · We describe an autosomal dominant form of CAD/MI (adCAD1) that is caused by the deletion of seven amino acids in transcription factor MEF2A.
  21. [21]
    Genetic susceptibility to myocardial infarction and coronary artery ...
    Oct 15, 2006 · Two gene variants in the leukotriene pathway (ALOX5AP and LTA4) have emerged as susceptibility factors for myocardial infarction (MI).
  22. [22]
    Eric Topol - TEDMED
    His work in the genomics of heart attack has led to discovery of genes (MEF2a deletion, THSB-4 variant) which led to recognition by the American Heart ...
  23. [23]
    The genetics of heart attack - PMC - NIH
    This paper will review the progress in this burgeoning and important field, to provide the reader with a perspective on how genetic information will someday ...
  24. [24]
    Emerging Genomic Applications in Coronary Artery Disease - PMC
    1, Eric J Topol. Eric J Topol, MD. 1Division of Cardiovascular Diseases ... Human genetic variation and its contribution to complex traits. Nat Rev Genet ...
  25. [25]
    Eric Topol Talks Empathy, Efficiency, and AI in Precision Medicine
    Apr 3, 2024 · For over a decade, Topol has urged colleagues to pursue an alternative screening approach using polygenic risk scores, a sentiment he reiterated ...<|separator|>
  26. [26]
    Study Details | Scripps Genomics Health Initiative | ClinicalTrials.gov
    Sponsor Scripps Translational Science Institute. Information provided by Eric Topol, MD, Scripps Translational Science Institute (Responsible Party). Last ...
  27. [27]
    Deep Medicine: How Artificial Intelligence Can Make Healthcare ...
    In Deep Medicine, leading physician Eric Topol reveals how artificial intelligence can help. AI has the potential to transform everything doctors do, from ...
  28. [28]
    High-performance medicine: the convergence of human ... - Nature
    Jan 7, 2019 · Keane, P. & Topol, E. With an eye to AI and autonomous diagnosis. NPJ Digit. Med. 1, 40 (2018). Abramoff ...
  29. [29]
    As artificial intelligence goes multimodal, medical applications multiply
    Sep 15, 2023 · As artificial intelligence goes multimodal, medical applications multiply. Eric J. Topol. https://orcid.org/0000-0002-1478-4729.
  30. [30]
    The generative era of medical AI - Cell Press
    Jul 10, 2025 · Theoretically, this integration mimics human reasoning, where physicians synthesize diverse information to form diagnoses, making multimodal AI ...
  31. [31]
    The generative era of medical AI - PubMed
    Jul 10, 2025 · ... AI, are transforming medicine through enhancements in diagnostics, patient interaction, and medical forecasting ... Eric Topol , Pranav Rajpurkar ...Missing: treatment | Show results with:treatment
  32. [32]
    Academic Publication | Eric Topol
    The clinical potential of counterfactual AI models. Sun-In Lee & Eric J Topol - Clinicians frequently use conditional reasoning for treatment decisions by ...
  33. [33]
    When Doctors With A.I. Are Outperformed by A.I. Alone - Ground Truths
    Feb 2, 2025 · A series of recent studies compared the performance of doctors with AI versus AI alone, spanning medical scans, diagnostic accuracy, and management reasoning.
  34. [34]
    A discussion with digital health pioneer Dr. Eric Topol - PMC - NIH
    Topol is a professor of genomics and the Gary and Mary West Endowed Chair of Innovative Medicine at the Scripps Research Institute in La Jolla, California. He ...Missing: biography | Show results with:biography<|separator|>
  35. [35]
    A decade of digital medicine innovation | Eric Topol
    Mar 23, 2021 · Eric J. Topol - Digital medicine is a new field that got its start around 2007, the time when smartphones were introduced.Missing: contributions | Show results with:contributions
  36. [36]
    Medical Selfies - by Eric Topol - Ground Truths
    Nov 30, 2022 · On the clinical side, as a cardiologist, I have used some form of handheld or smartphone ultrasound in place of a stethoscope since 2009.Missing: diagnostics | Show results with:diagnostics
  37. [37]
    Scripps Translational Science Institute, Nature Research launch ...
    Feb 2, 2018 · In the inaugural editorial, Topol and Steinhubl define digital medicine as the use of “digital tools to upgrade the practice of medicine to one ...
  38. [38]
    The top 5 innovations in digital clinical trials that offer a glimpse into ...
    Dec 21, 2023 · Eric Topol, MD, notes PROGRESS as “one of the most exciting trials ever done digitally.” In this study, participants are able to track their ...
  39. [39]
    Spotting COVID-19 infections with wearable devices: A new AI ...
    Dec 8, 2021 · A new AI-based system developed by researchers at Scripps Research Translational Institute (SRTI) has the potential to identify COVID-19 cases ...<|control11|><|separator|>
  40. [40]
    Eric Topol authors book on the science of healthy aging
    May 6, 2025 · This eye-opening book reveals that the secret to longevity lies not in the miracle of anti-aging pills, but in groundbreaking scientific advancements.
  41. [41]
    New book explores the science behind 'super aging' and longer ...
    Aug 2, 2025 · Dr. Eric Topol, Author, "Super Agers": A superager we could roughly define as somebody over age 85 who's never had cancer, heart disease or any ...
  42. [42]
    Super Agers by Eric Topol | Summary, Quotes, FAQ, Audio - SoBrief
    Rating 4.3 (676) Jun 11, 2025 · Hallmarks of aging: The book describes 12 interconnected hallmarks, including genome instability, telomere attrition, and mitochondrial ...
  43. [43]
    The Drivers of Age-Related Diseases - by Eric Topol - Ground Truths
    Jun 8, 2025 · A new epigenetic age clock connects the dots between aging, the immune system, inflammation and lifestyle factors.
  44. [44]
    How the Science of Aging Can Extend Healthspan - Ground Truths
    Apr 21, 2025 · How the Science of Aging Can Extend Healthspan. A Time of Optimism for Primary Prevention of the Major Age-Related Diseases. Eric Topol. Apr 21 ...
  45. [45]
    'Super Agers' author Eric Topol shares how to feel 50 at 80
    Jun 6, 2025 · If there is one main thesis to Topol's book, it's that healthy aging is a function of a strong immune system, which can defend against ...
  46. [46]
    TSRI Awarded $20M for First Year of US Precision Medicine ...
    Jul 18, 2016 · Eric Topol, who is director of STSI, professor of genomics at TSRI and chief academic officer at Scripps Health, will direct the grant, which ...Missing: involvement | Show results with:involvement
  47. [47]
    Towards a Deeper and More Human-centric Medicine
    May 19, 2021 · In 2016, Topol was awarded a $207 million grant from the NIH to help lead the Precision Medicine Initiative Cohort Program, now called the All ...
  48. [48]
    Topol Charts AI Path to More Accuracy in Medicine - NIH Record
    Sep 3, 2021 · In 2016, NIH awarded him a $207 million grant to help lead the Precision Medicine Initiative Cohort Program (now known as All of Us Research).
  49. [49]
    Leveraging technology to democratize health - UCSF Alumni
    Cardiologist Eric Topol is turning the medical establishment on its ear with ... I've only had three jobs in my life – at the University of Michigan ...
  50. [50]
    Podcast: Eric Topol on the Science of Super-Aging and Longevity
    May 6, 2025 · He's a practicing cardiologist, and with all of his free time, the author of three bestselling works of nonfiction about health, medicine, and ...Missing: achievements | Show results with:achievements
  51. [51]
    Eric Topol - AI for Good - ITU
    In 2016, Topol was awarded a $207M grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research ...
  52. [52]
    Review announced into training NHS staff to use AI and robotics
    Apr 27, 2018 · The review will be led by Dr Eric Topol an expert in cardiology, genetics and digital medicine. Dr Topol will look at opportunities where ...
  53. [53]
    Preparing the healthcare workforce to deliver the digital future
    The Topol Review outlined recommendations to ensure the NHS is the world leader in using digital technologies to benefit patients.
  54. [54]
    Technology will improve doctors' relationships with patients, says ...
    Feb 11, 2019 · Doctors should be trained in genomics, artificial intelligence (AI), and digital healthcare technologies, the government commissioned Topol review has said.<|separator|>
  55. [55]
    The Topol review: creating a digitally savvy health care workforce
    Ground breaking review debates how technology will impact the NHS workforce · Tackling the differences in digital literacy of the current workforce · But with the ...
  56. [56]
    Topol Digital Fellowships
    The Topol Digital Fellowship, an NHS Digital Academy programme, is designed to equip fellows with new skills and knowledge. These will include: how to ...What is the programme?Meet our fellows
  57. [57]
    UK National Health Service launches Topol Program for Digital ...
    Feb 26, 2019 · Program supports workforce training recommended by Eric Topol, MD, in an independent review of the digital future of the National Health Service.
  58. [58]
    Topol Programme for Digital Fellowships
    The Topol Programme for Digital Fellowships in Healthcare aims to support NHS organisations to invest in clinical staff to develop specialist digital skills ...
  59. [59]
    Health Education England celebrates progress on Topol ...
    Feb 24, 2023 · A review into the progress made on recommendations made in the 2019 Topol Review has been released by Health Education England.
  60. [60]
    Topol digital fellowship aspirants: Understanding the motivations ...
    The Topol Programme for Digital Fellowships in Healthcare is a flagship national programme for digital health aspirants in England.
  61. [61]
    [PDF] Preparing the healthcare workforce to deliver the digital future
    ... benefits these digital healthcare technologies offer. I would like to ... Health and Social Care, invited Dr Eric Topol to lead an independent review ...
  62. [62]
    Technology and humanity in healthcare: the Topol Review
    Feb 11, 2019 · Gathering the evidence · Setting the baseline for the new medicine · A new role for patients and citizens · Getting the most out of genomics.
  63. [63]
    Applications of digital technology in COVID-19 pandemic ... - PubMed
    This Viewpoint provides a framework for the application of digital technologies in pandemic management and response.
  64. [64]
    Applications of digital technology in COVID-19 pandemic planning ...
    Mar 23, 2021 · This Viewpoint provides a framework for the application of digital technologies in pandemic management and response, highlighting ways in which ...
  65. [65]
    Risk of cardiovascular events associated with selective COX-2 ...
    Our search yielded 2 major randomized trials, the Vioxx Gastrointestinal Outcomes Research Study (VIGOR; 8076 patients) and the Celecoxib Long-term Arthritis ...
  66. [66]
    https://jamanetwork.com/journals/jama/fullarticle/194284
  67. [67]
    [PDF] The sad story of Vioxx, and what we should learn from it
    Sep 30, 2004 · ERIC J. TOPOL, MD. Chairman, Department of. Cardiovascular Medicine,. The Cleveland Clinic Foundation. The sad story of Vioxx, and what we ...Missing: controversy | Show results with:controversy
  68. [68]
    Doctor: Merck's Habits 'Appalling' - CBS News
    Dec 4, 2005 · A prominent cardiologist testifying in Merck & Co.'s federal trial over Vioxx accused the drug maker of engaging in scientific misconduct.
  69. [69]
    None
    Nothing is retrieved...<|control11|><|separator|>
  70. [70]
    Rofecoxib, Merck, and the FDA | New England Journal of Medicine
    Dec 30, 2004 · Topol neglects to mention that beginning in 2000, Merck undertook three prospective, randomized, placebo-controlled trials of Vioxx in more than ...
  71. [71]
    Topol denies Vioxx conflict of interest - Medscape
    Dec 2, 2004 · Dr Eric Topol denies conflict of interest over Vioxx condemnation · Had no knowledge of any investment by the Great Point Partners fund in Merck ...
  72. [72]
    Vioxx Critic Defends Self - Forbes
    Dec 1, 2004 · In today's statement, Topol says that he was retained by Great Point Partners for a fee of $12,000 per year. However, he says, he never ...
  73. [73]
    Doctor cuts Wall Street ties to avoid potential conflict - Cleveland 19
    Jan 26, 2005 · Topol said he didn't know Great Point Partners' Biomedical Value fund was short selling Merck and that he had no financial interest in the fund.
  74. [74]
    Merck recalls rofecoxib due to increased cardiovascular risk - Healio
    Nov 1, 2004 · Topol and Nissen said the risk was 3.5% among patients taking rofecoxib compared to 1.9% among patients taking placebo. “This was in a trial ...
  75. [75]
    Eric Topol loses titles at Cleveland Clinic - Medscape
    Dec 12, 2005 · He is still chief of cardiovascular medicine for the Cleveland Clinic and remains a professor of medicine at the college and a professor of ...Missing: initial | Show results with:initial
  76. [76]
    Topol's Exit - Forbes
    Feb 9, 2006 · Her lawyers argue that Vioxx caused Irwin's heart-attack death. That case ended in a deadlock and is being retried in New Orleans. Topol's ...<|separator|>
  77. [77]
    High-Profile Doctor to Leave Position at Cleveland Clinic
    Feb 10, 2006 · Eric J. Topol, is leaving for academia after a divisive yearlong dispute with the clinic's chief executive, Dr. Delos M. Cosgrove. Both Dr.Missing: initial | Show results with:initial
  78. [78]
    One doctor's campaign to stop a covid-19 vaccine being rushed ...
    Oct 19, 2020 · One doctor's campaign to stop a covid-19 vaccine being rushed through before Election Day. How heart doctor Eric Topol used his social-media ...<|separator|>
  79. [79]
    Opinion | Coronavirus Vaccine Trials Could Suffer From Shortcuts
    Sep 22, 2020 · These coronavirus trials don't answer the one question we need to know. We may not find out whether the vaccines prevent moderate or severe cases of Covid-19.
  80. [80]
    Dr. Eric Topol on variants, vaccines and AstraZeneca's data reporting
    Mar 25, 2021 · Topol calls drug maker AstraZeneca's recent controversial under-reporting of complete safety data to US regulators for its COVID-19 vaccine ...
  81. [81]
    It's not too late - Science
    Eric Topol attributes the Biden Administration's disappointing Covid-19 pandemic response largely to failure of data collection: “during the Omicron wave ...<|control11|><|separator|>
  82. [82]
    'Historic Botched Job': CDC's, Others' Failed COVID Communication
    Feb 25, 2022 · This is Eric Topol for Medscape's Medicine and the Machine. We have an exciting podcast today with Dr Randy Olson. Randy was a marine biologist, ...
  83. [83]
    Covid, 4 years on - by Eric Topol - Ground Truths
    Mar 13, 2024 · We're still learning every day about SARS-CoV-2's impact, its evolution, protection from vaccination, and more. Here's a quick summary of what I think is worth ...
  84. [84]
    Separating Facts from Myths in the Pandemic - Scott Barry Kaufman
    Topol is optimistic about the future of the pandemic and outlines things coming down the horizon that should give us hope. But as we discussed, the major ...Missing: controversies | Show results with:controversies
  85. [85]
    The Indomitable Covid Virus - by Eric Topol - Ground Truths - Substack
    Aug 3, 2024 · Yesterday Bernie Sanders proposed a new moonshot fund of $1 billion per year for 10 years for dedicated Long Covid research.. That's terrific ...Missing: controversies | Show results with:controversies
  86. [86]
    Eric Topol pens book on artificial intelligence in medicine
    Mar 12, 2019 · New book shows how artificial intelligence will empower physicians and patients with potential to revolutionize healthcare---and bring back the care.
  87. [87]
    Eric Topol | Official Publisher Page - Simon & Schuster
    Dr. Topol writes the Substack newsletter Ground Truths and is the author of The Creative Destruction of Medicine, The Patient Will See You Now, Deep Medicine, ...
  88. [88]
    The Creative Destruction of Medicine - Hachette Book Group
    In stock Free delivery over $35How genomics, big data, and digital technology are revolutionizing every aspect of medicine, from physical exams to drug prescriptions to organ transplants
  89. [89]
    Book Received—The Creative Destruction of Medicine: How the ...
    Book Received—The Creative Destruction of Medicine ... Author: Eric Topol M.D.. Publication Date: January 31, 2012 ... AME Medical Journal · AME Surgical Journal ...
  90. [90]
    The Patient Will See You Now: The Future of Medicine is in Your ...
    Publication date. January 6, 2015. Language. English. Dimensions. 6.5 x 1.25 x ... Topol's new book, The Patient Will See You Now. Building on themes he ...
  91. [91]
    Super Agers | Book by Eric Topol - Simon & Schuster
    4–8 day deliverySuper Agers is a detailed guide to a revolution transforming human longevity. This is a breakthrough moment in the history of human health care.
  92. [92]
    Super Agers: An Evidence-Based Approach to Longevity: Topol, Eric
    Eric Topol explores groundbreaking medical advances in treating chronic diseases and aging, offering evidence-based strategies for extending healthy human ...
  93. [93]
    One-on-One with Eric Topol - Apple Podcasts
    Rating 4.7 (16) Medscape Editor-in-Chief Eric Topol interviews leading experts on the latest clinical, scientific, social, political, and legal developments that affect the ...Missing: media | Show results with:media
  94. [94]
    Medscape Podcasts | Eric Topol
    Dr Eric Topol and Dr Robert Harrington interview Dr Abraham Verghese about his fiction writing methods and Oprah's enthusiasm for his latest novel. Listen to…Missing: appearances | Show results with:appearances
  95. [95]
    Chronic Lead Exposure, a Risk Factor for Heart Disease
    Aug 17, 2025 · Guest column by Eric Topol, MD. The buildup of cholesterol and other substances in the wall of our arteries, known as atherosclerosis, is ...Missing: media | Show results with:media
  96. [96]
    Comments - Towards an Optimal Diet - by Eric Topol - Ground Truths
    Nov 5, 2023 · Dr. Topol lays out a compelling case for investment in research and action on nutrition, starting with the eye-popping stat that a systematic study showed a ...Missing: media | Show results with:media
  97. [97]
    Eric J. Topol: Immunity's down. Infection rates are up. And what ...
    Dec 10, 2022 · Infection rates are up. And what happened to everyone's masks? From the commentary: We don't know how severe the new COVID wave will be. ...
  98. [98]
    He hunted for gold-standard research on AI in medicine - Stat News
    and how much hype is out ...
  99. [99]
    Dr. Eric Topol: Can AI Fix Our Health and Our Healthcare System?
    Feb 14, 2024 · I talk to Dr. Eric Topol about how AI is transforming the landscape of healthcare and why it is essential to a wellness-centered future.
  100. [100]
    Advocating for a Master of Digital Health Degree | Eric Topol, MD
    Jan 16, 2025 · Our JAMA, Journal of the American Medical Association essay today for why we should develop a Master of Digital Health (MDH) degree ...
  101. [101]
    Forget just living longer. Eric Topol wants to help Americans live ...
    Oct 1, 2025 · In "Super Agers," the writer and medical researcher maps a path to extending healthspan with AI, targeted drugs, and lifestyle changes.
  102. [102]
    How to Become a “Super Ager:” The Science-Backed Secrets ... - PBS
    Jul 11, 2025 · Dr. Eric Topol discusses his new book “Super Agers.”<|separator|>
  103. [103]
    High hopes for Deep Medicine? AI, economics, and the future of care
    Jul 29, 2025 · In Deep Medicine, Eric Topol [2019] argues that the development of artificial intelligence (AI) for healthcare will lead to a dramatic shift ...
  104. [104]
    Eric J. Topol: Medicine H-index & Awards - Academic Profile
    Eric J. Topol performs integrative Endocrinology and Internal medicine research in his work. He performs multidisciplinary study in Randomized controlled trial ...
  105. [105]
    Eric J. Topol, M.D., Elected To Institute Of Medicine Of The National ...
    Oct 19, 2005 · Dr. Topol lives in Chagrin Falls with his wife, Susan. They are the parents of two children, Sarah and Evan. The Cleveland Clinic Foundation, ...Missing: biography | Show results with:biography
  106. [106]
    Eric Topol, M.D. | Exclusive Keynote Speaker - Leigh Bureau
    Dr. Eric Topol is an internationally renowned physician-scientist known for his pioneering work using artificial intelligence, deep data, and genomics.
  107. [107]
    Dr. Topol Presented 2011 TCT Career Achievement Award
    Nov 8, 2011 · Scripps Health's Eric J. Topol, MD, a world-renowned cardiologist and physician-scientist, was presented the 2011 TCT Career Achievement Award ...
  108. [108]
    Scripps Cardiologist Honored by Clinical Laboratory Group - San ...
    Jul 27, 2014 · Eric Topol, MD, was honored with the Wallace H. Coulter Lectureship from the American Association for Clinical Chemistry.
  109. [109]
    Professor Eric J. Topol, 2016 Rambam Award Recipient - YouTube
    Jun 1, 2016 · Rambam Health Care Campus is proud and honored to bestow the 2016 Rambam Award upon Professor Eric J. Topol in recognition of his medical ...Missing: professional | Show results with:professional
  110. [110]
    Eric Topol receives Gold Foundation medal for humanism in ...
    The Arnold P. Gold Foundation awarded its National Humanism in Medicine Medal to Eric Topol, MD, founder and director of the Scripps Research Translational ...Missing: professional | Show results with:professional
  111. [111]
    Eric Topol receives Distinguished Health Communications award ...
    Eric Topol, MD, was honored at the 2024 Friends of the National Library of Medicine (NLM) Awards Gala on Tuesday, September 10, 2024.Missing: professional | Show results with:professional
  112. [112]
    ‪Eric Topol‬ - ‪Google Scholar‬
    Deep medicine: how artificial intelligence can make healthcare human again. E Topol. Hachette UK, 2019. 2658, 2019 ; AI in health and medicine. P Rajpurkar, E ...Missing: diagnostics | Show results with:diagnostics
  113. [113]
    The Next Phase of Ground Truths - by Eric Topol
    Mar 13, 2023 · I've had 3 jobs: at the University of Michigan, Cleveland Clinic, and Scripps Research. Along the way, I started a new medical school at ...<|separator|>
  114. [114]
    World's Best Medicine Scientists - Research.com
    Each scientist's position within the ranking is derived from their D-index (Discipline H-index), a metric that exclusively considers publications and citation ...
  115. [115]
    Eric J. Topol, MD - The American Society for Clinical Investigation
    Honors / awards. National Academy of Medicine (2004). The American Society for Clinical Investigation Ann Arbor, MI 48104 staff@the-asci.org. News · Meetings ...
  116. [116]
    Eric Topol, MD - La Jolla - Scripps Health
    Biography. Eric Topol, MD, is a practicing cardiologist with Scripps Clinic and a pioneer in the field of cardiovascular medicine. In his productive career ...
  117. [117]
    Dr. Anthony Fauci, Dr. Wayne Riley, Dr. Eric Topol - Gold Foundation
    Jan 14, 2021 · Gold Foundation medals to be awarded to 3 titans of humanism in healthcare: Dr. Anthony Fauci, Dr. Wayne Riley, Dr. Eric Topol · About Anthony ...
  118. [118]
    Eric Topol, M.D., will be honored with the Friends of the National ...
    Eric Topol, M.D., will be honored with the Friends of the National Library of Medicine's (FNLM) DONALD AB LINDBERG DISTINGUISHED HEALTH COMMUNICATIONS AWARD.
  119. [119]
    Eric Topol's tough prescription for improving medicine – San Diego ...
    Sep 15, 2012 · Topol said he was asked to draw up plans for a small medical school at The Scripps Research Institute that would focus heavily on training ...Missing: York | Show results with:York
  120. [120]
    Dr. Eric Topol's Super-Ager Longevity Habits - Men's Fitness
    Sep 17, 2025 · At 71, Dr. Eric Topol credits strength training, REM sleep, and a Mediterranean diet for keeping his heart age 13 years younger.
  121. [121]
    Dr. Eric Topol: What The Future of Aging Looks Like | TIME
    May 8, 2025 · Her remarkable health span isn't shared by her family members. Her mother died at 59; her father at 64. Her two brothers died at 43 and 75.Missing: biography childhood